EP3400945A4 - Polymerderivat von macrolid-immunosuppressiva - Google Patents

Polymerderivat von macrolid-immunosuppressiva Download PDF

Info

Publication number
EP3400945A4
EP3400945A4 EP16883771.4A EP16883771A EP3400945A4 EP 3400945 A4 EP3400945 A4 EP 3400945A4 EP 16883771 A EP16883771 A EP 16883771A EP 3400945 A4 EP3400945 A4 EP 3400945A4
Authority
EP
European Patent Office
Prior art keywords
polymer derivative
macrolide immunosuppressant
macrolide
immunosuppressant
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP16883771.4A
Other languages
English (en)
French (fr)
Other versions
EP3400945A1 (de
Inventor
Nao Yoneki
Akihiro Sekiguchi
Kana Mizunuma
Yuki Kobayashi
Junpei Konno
Kan Saiga
Keiichirou Yamamoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nippon Kayaku Co Ltd
Original Assignee
Nippon Kayaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Kayaku Co Ltd filed Critical Nippon Kayaku Co Ltd
Publication of EP3400945A1 publication Critical patent/EP3400945A1/de
Publication of EP3400945A4 publication Critical patent/EP3400945A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/40—Polyamides containing oxygen in the form of ether groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/02—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
    • C08G69/08—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
    • C08G69/10—Alpha-amino-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/48—Polymers modified by chemical after-treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Polyamides (AREA)
  • Polyethers (AREA)
EP16883771.4A 2016-01-08 2016-12-19 Polymerderivat von macrolid-immunosuppressiva Withdrawn EP3400945A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016002678 2016-01-08
PCT/JP2016/087774 WO2017119272A1 (ja) 2016-01-08 2016-12-19 マクロライド系免疫抑制剤の高分子誘導体

Publications (2)

Publication Number Publication Date
EP3400945A1 EP3400945A1 (de) 2018-11-14
EP3400945A4 true EP3400945A4 (de) 2019-09-11

Family

ID=59273595

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16883771.4A Withdrawn EP3400945A4 (de) 2016-01-08 2016-12-19 Polymerderivat von macrolid-immunosuppressiva

Country Status (5)

Country Link
US (1) US10945997B2 (de)
EP (1) EP3400945A4 (de)
JP (1) JP6830907B2 (de)
TW (1) TW201726131A (de)
WO (1) WO2017119272A1 (de)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999003860A1 (en) * 1997-07-15 1999-01-28 Kuhnil Pharmaceutical Co., Ltd. Water soluble polymer-tacrolimus conjugated compounds and process for preparing the same
US6395254B1 (en) * 1995-12-21 2002-05-28 Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts Conjugate comprising an active agent, a polypeptide and a polyether
WO2016136641A1 (ja) * 2015-02-23 2016-09-01 日本化薬株式会社 生理活性物質結合ブロック共重合体

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5247076A (en) 1991-09-09 1993-09-21 Merck & Co., Inc. Imidazolidyl macrolides having immunosuppressive activity
JP4462928B2 (ja) 2001-06-20 2010-05-12 日本化薬株式会社 不純物含有量の低減したブロック共重合体、高分子担体及び高分子医薬製剤並びにその製造方法
ATE483476T1 (de) 2003-03-20 2010-10-15 Nippon Kayaku Kk Micellen-zubereitung mit schwer wasserlöslichem anti-krebsmittel und neuem blockcopolymer
WO2005079861A2 (en) * 2004-02-13 2005-09-01 Safeway Investments Ltd. Polymeric water soluble prodrugs
US20060134166A1 (en) * 2004-05-25 2006-06-22 Luthra Ajay K Absorbable biocompatible materials
KR101312417B1 (ko) 2005-05-11 2013-09-27 니폰 가야꾸 가부시끼가이샤 시티딘계 대사길항제의 고분자 유도체
US8323669B2 (en) 2006-03-28 2012-12-04 Nippon Kayaku Kabushiki Kaisha Polymer conjugate of taxane
CA2664852A1 (en) 2006-10-03 2008-04-10 Nippon Kayaku Kabushiki Kaisha High-molecular weight conjugate of resorcinol derivatives
CN102421827B (zh) * 2009-05-15 2014-07-30 日本化药株式会社 具有羟基的生理活性物质的高分子结合体
AR090736A1 (es) 2012-04-20 2014-12-03 Sucampo Ag Conjugado de compuesto triciclo-polimero
JP2017160125A (ja) 2014-08-04 2017-09-14 日本化薬株式会社 核酸代謝拮抗剤が結合したポリアミノ酸誘導体。
EP3378494A4 (de) 2015-11-18 2019-07-31 Nippon Kayaku Kabushiki Kaisha Polymerisches derivat von macrolid-immunosuppressiva

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395254B1 (en) * 1995-12-21 2002-05-28 Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts Conjugate comprising an active agent, a polypeptide and a polyether
WO1999003860A1 (en) * 1997-07-15 1999-01-28 Kuhnil Pharmaceutical Co., Ltd. Water soluble polymer-tacrolimus conjugated compounds and process for preparing the same
WO2016136641A1 (ja) * 2015-02-23 2016-09-01 日本化薬株式会社 生理活性物質結合ブロック共重合体
EP3263107A1 (de) * 2015-02-23 2018-01-03 Nippon Kayaku Kabushiki Kaisha Blockcopolymerkonjugat aus einem physiologisch aktiven stoff

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2017119272A1 *

Also Published As

Publication number Publication date
US20200155518A1 (en) 2020-05-21
JPWO2017119272A1 (ja) 2018-11-01
TW201726131A (zh) 2017-08-01
WO2017119272A1 (ja) 2017-07-13
US10945997B2 (en) 2021-03-16
JP6830907B2 (ja) 2021-02-17
EP3400945A1 (de) 2018-11-14

Similar Documents

Publication Publication Date Title
EP3615539A4 (de) 2-aminochinolinderivate
EP3302068A4 (de) Streptomyceten
EP3450452A4 (de) Modifiziertes fibroin
EP3416714A4 (de) Katheter mit geschlossenem system
EP3259246A4 (de) Derivate von sobetirom
EP3450451A4 (de) Modifiziertes fibroin
EP3111680A4 (de) Netzwerkbereichserweiterer mit multi-rf-funkunterstützung für mehrere netzwerkschnittstellen
EP3113825A4 (de) Dilatorhülsensatz
EP3376976A4 (de) Trokarträger
EP3457851A4 (de) Derivate von sobetirom
EP3458470A4 (de) Neuartige cyclosporinderivate und verwendungen davon
EP3476859A4 (de) Modifiziertes fibroin
EP3769703A4 (de) Dilatator
EP3252899A4 (de) Polymerkanüle
EP3156410A4 (de) Polyen-makrolid-derivat
EP3322414A4 (de) Verfahren zur verhinderung der toxizität von platinarzneimitteln
EP3445262A4 (de) Trokare
EP3134415A4 (de) Verbessertes verfahren zur herstellung von rifamyciderivaten
EP3238730A4 (de) Pharmazeutische zubereitung von camptothecin-haltigem polymerderivat
EP3518924A4 (de) Feste dispersionsformen von rifaximin
EP3563266A4 (de) Normalisierung von sensoren
EP3272750A4 (de) Morphinanderivat
EP3546462A4 (de) Neuartiges oxoisochinolinderivat
EP3343944A4 (de) Lautsprechersystem für bewegtkörper
EP3217972A4 (de) Aus mevalonolacton hergestellte polymere und derivate

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20180802

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20190813

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/706 20060101AFI20190807BHEP

Ipc: A61K 31/787 20060101ALI20190807BHEP

Ipc: A61P 11/00 20060101ALI20190807BHEP

Ipc: A61P 19/02 20060101ALI20190807BHEP

Ipc: A61K 47/50 20170101ALI20190807BHEP

Ipc: A61P 37/08 20060101ALI20190807BHEP

Ipc: C08G 69/48 20060101ALI20190807BHEP

Ipc: A61K 47/34 20170101ALI20190807BHEP

Ipc: A61P 1/04 20060101ALI20190807BHEP

Ipc: A61P 29/00 20060101ALI20190807BHEP

Ipc: A61P 37/06 20060101ALI20190807BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20201028

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20210728